IL-23IL-23

Back to Disease

October 2025

Medication Review: What Is the Evidence For Guselkumab Efficacy In Inhibiting The Progression of Structural Damage?

October 2025

What Is the Clinical Significance of Structural Damage in PsA?

March 2025

Long-Term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis)

October 2025

What is the Effect of Guselkumab on Structural Damage in PsA?

May 2025

What is the Real World Evidence of Guselkumab in PsA

November 2024

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

April 2025

What is the Efficacy of Guselkumab Across the GRAPPA Domains?

September 2024

Data Review From the Phase III DISCOVER-2 Trials

July 2024

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

December 2024

What Is the Safety Profile of Guselkumab in PsO and PsA?

sectionimg

dotsimg

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play